Julianne Flanagan to Veterans
This is a "connection" page, showing publications Julianne Flanagan has written about Veterans.
Connection Strength
2.498
-
Enhancing prolonged exposure therapy for PTSD among veterans with oxytocin: Design of a multisite randomized controlled trial. Contemp Clin Trials. 2020 08; 95:106074.
Score: 0.405
-
Effects of oxytocin on stress reactivity and craving in veterans with co-occurring PTSD and alcohol use disorder. Exp Clin Psychopharmacol. 2019 Feb; 27(1):45-54.
Score: 0.362
-
Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial. J Psychiatr Res. 2018 03; 98:64-69.
Score: 0.341
-
A Double-Blind Randomized Controlled Trial of Doxazosin for Co-Occurring PTSD and Alcohol Use Disorder in Veterans. J Clin Psychiatry. 2023 Mar 08; 84(2).
Score: 0.122
-
COPE and oxytocin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in U.S. military veterans. Contemp Clin Trials. 2023 03; 126:107084.
Score: 0.121
-
Putting the pieces together to understand anger in combat veterans and service members: Psychological and physical contributors. J Psychiatr Res. 2023 03; 159:57-65.
Score: 0.121
-
Temporal dynamics of symptom change among veterans receiving an integrated treatment for posttraumatic stress disorder and substance use disorders. J Trauma Stress. 2022 04; 35(2):546-558.
Score: 0.112
-
STRONG STAR and the Consortium to Alleviate PTSD: Shaping the future of combat PTSD and related conditions in military and veteran populations. Contemp Clin Trials. 2021 11; 110:106583.
Score: 0.111
-
Craving Moderates the Effects of Intranasal Oxytocin on Anger in Response to Social Stress Among Veterans With Co-Occurring Posttraumatic Stress Disorder and Alcohol Use Disorder. J Clin Psychopharmacol. 2021 Jul-Aug 01; 41(4):465-469.
Score: 0.109
-
Ethnoracial differences in treatment-seeking veterans with substance use disorders and co-occurring PTSD: Presenting characteristics and response to integrated exposure-based treatment. J Ethn Subst Abuse. 2022 Jul-Sep; 21(3):1141-1164.
Score: 0.104
-
Veterans with PTSD and comorbid substance use disorders: Does single versus poly-substance use disorder affect treatment outcomes? Drug Alcohol Depend. 2019 06 01; 199:70-75.
Score: 0.093
-
Substance use disorders and PTSD: Examining substance use, PTSD symptoms, and dropout following imaginal exposure. Addict Behav. 2019 03; 90:35-39.
Score: 0.090
-
Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans. Contemp Clin Trials. 2018 10; 73:8-15.
Score: 0.089
-
The Role of Relationship Adjustment in an Integrated Individual Treatment for PTSD and Substance Use Disorders Among Veterans: An Exploratory Study. J Dual Diagn. 2017 Jul-Sep; 13(3):213-218.
Score: 0.082
-
Relations among social support, PTSD symptoms, and substance use in veterans. Psychol Addict Behav. 2016 Nov; 30(7):764-770.
Score: 0.079
-
Family composition and symptom severity among Veterans with comorbid PTSD and substance use disorders. Addict Behav. 2015 Nov; 50:117-23.
Score: 0.072
-
N-acetylcysteine for the treatment of comorbid alcohol use disorder and posttraumatic stress disorder: Design and methodology of a randomized clinical trial. Contemp Clin Trials. 2020 04; 91:105961.
Score: 0.025
-
Treatment of co-occurring posttraumatic stress disorder and substance use: Does order of onset influence outcomes? Psychol Trauma. 2018 Nov; 10(6):662-665.
Score: 0.021
-
Integrated, exposure-based treatment for PTSD and comorbid substance use disorders: Predictors of treatment dropout. Addict Behav. 2017 10; 73:30-35.
Score: 0.020
-
Habituation of distress and craving during treatment as predictors of change in PTSD symptoms and substance use severity. J Consult Clin Psychol. 2017 Mar; 85(3):274-281.
Score: 0.020